Tuesday, March 21, 2017 10:21:41 AM
duration;
We currently have a non-exclusive license on U.S. patent application #20130190274, Topical Drug Delivery System with Dual Carriers. We licensed this patent from Dr. Phillips.
This is in the same Disclosure Statement uploaded 12.29.16 that states Viabecline is based on the patent owned by Phillips/Keough--#20130190274
http://www.otcmarkets.com/financialReportViewer?symbol=VDRM&id=164573
The excerpt below was in my last post and from the same disclosure.
A. Business Development:
ViaDerma, Inc’s lead product is an FDA registered topical antibiotic called Viabecline...The products are based on a patent pending delivery system technology that allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM